Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

76.23 +1.51 (+2.02%)
Streaming Delayed Price Updated: 10:32 AM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 120,703
Open 74.26
Bid (Size) 75.44 (100)
Ask (Size) 76.36 (200)
Prev. Close 74.72
Today's Range 73.00 - 76.23
52wk Range 0.4320 - 78.81
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Performance

YTD
+75.6%
+75.6%
1 Month
+10.2%
+10.2%
3 Month
+71.4%
+71.4%
6 Month
+27.2%
+27.2%
1 Year
+15444.5%
+15444.5%

More News

Read More
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NEKTAR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
2 Healthcare Stocks to Buy Before They Get Bought Out ↗
Via The Motley Fool
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Deadline Approaching: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire

Frequently Asked Questions

Is Nektar Therapeutics - Common Stock publicly traded?
Yes, Nektar Therapeutics - Common Stock is publicly traded.
What exchange does Nektar Therapeutics - Common Stock trade on?
Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nektar Therapeutics - Common Stock?
The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market
What is the current price of Nektar Therapeutics - Common Stock?
The current price of Nektar Therapeutics - Common Stock is 76.23
When was Nektar Therapeutics - Common Stock last traded?
The last trade of Nektar Therapeutics - Common Stock was at 04/07/26 10:32 AM ET
What is the market capitalization of Nektar Therapeutics - Common Stock?
The market capitalization of Nektar Therapeutics - Common Stock is 14.01B
How many shares of Nektar Therapeutics - Common Stock are outstanding?
Nektar Therapeutics - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS